Vaxart to Present at the 29th European Congress of Clinical Microbiology & Infectious Diseases
April 12 2019 - 08:00AM
Business Wire
100% Survival Against Lethal H5N1 Avian Flu
Challenge in Ferret Study
Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology
company developing oral recombinant vaccines that are administered
by tablet rather than by injection, today announced that Roberto
Mateo, Ph.D., lead scientist at Vaxart, will present preclinical
data in a poster presentation at the 29th European Congress of
Clinical Microbiology and Infectious Diseases showing that Vaxart’s
oral quadrivalent influenza vaccine conferred 100% protection
against a lethal H5N1 avian influenza challenge in ferrets.
Details of the presentation are as follows:
Poster Title: Oral adenovirus-based quadrivalent
influenza vaccine protects ferrets from lethal challenge with a
pandemic H5N1 influenza virus (Vietnam H5N1)Poster Number:
P0386Date & Time: Saturday, April 13, 2019 at 3:30 –
4:30 PM GMTAuthors: Roberto Mateo, et al.Session:
Vaccination: from bench to practice
The Vaxart oral quadrivalent influenza vaccine was compared
head-to-head with placebo and quadrivalent injectable Fluzone® in
ferrets that received a lethal challenge of H5N1 avian influenza 28
days post immunization. The Vaxart quadrivalent vaccine was matched
with the quadrivalent Fluzone, covering the same four influenza
strains. Neither the Vaxart quadrivalent vaccine nor the
quadrivalent Fluzone covered H5N1 strains. Both vaccines were
administered at an equivalent dose and animals were followed for 15
days after challenge. Ferrets in the placebo group had a 25%
survival rate while 62% of the animals in the Fluzone group
survived. In contrast, 100% of the animals receiving the oral
Vaxart vaccine survived.
“This is another clear demonstration of the ability of our oral
influenza vaccine to provide protection against divergent influenza
strains such as H5N1 avian flu,” said Wouter Latour, M.D., chief
executive officer of Vaxart. “This result complements the data from
our recent human challenge study, and solidifies the body of
evidence demonstrating that our oral vaccines have the potential to
provide improved protection against influenza compared to
injectable inactivated vaccines.”
The Phase 2 study was completed with support from Biomedical
Advanced Research and Development Authority (BARDA). Vaxart
received a $13.9 million contract from BARDA in September 2015 to
support the advanced development of more effective influenza
vaccines to ultimately improve seasonal and pandemic influenza
preparedness. The contract was increased to $15.7 million in
2017.
The project has been funded in whole or in part with federal
funds from the Department of Health and Human Services’ Office of
the Assistant Secretary for Preparedness and Response; Biomedical
Advanced Research and Development Authority under Contract No.
HHSO100201500034C.
About Vaxart
Vaxart is a clinical-stage biotechnology company focused on
developing oral recombinant protein vaccines based on its
proprietary oral vaccine platform. Vaxart’s vaccines are designed
to generate broad and durable immune responses that protect against
a wide range of infectious diseases and may also be useful for the
treatment of chronic viral infections and cancer. Vaxart’s vaccines
are administered using a convenient room temperature-stable tablet,
rather than by injection. Vaxart believes that tableted vaccines
are easier to distribute and administer than injectable vaccines
and have the potential to significantly increase vaccination rates.
Vaxart’s development programs include oral tablet vaccines that are
designed to protect against norovirus, seasonal influenza and
respiratory syncytial virus (RSV), as well as a therapeutic vaccine
for human papillomavirus (HPV).
Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that
involve substantial risks and uncertainties. All statements, other
than statements of historical facts, included in this press release
regarding our strategy, prospects, plans and objectives, results
from preclinical and clinical trials, commercialization agreements
and licenses, beliefs and expectations of management are
forward-looking statements. These forward-looking statements may be
accompanied by such words as “believe,” “could,” “potential,”
“will” and other words and terms of similar meaning. Examples of
such statements include, but are not limited to, statements
relating to the Vaxart’s ability to develop and commercialize its
product candidates and clinical results and trial data; and
Vaxart’s expectations with respect to the advantages it believes
its oral vaccine platform can offer over injectable alternatives,
particularly for mucosal pathogens such as norovirus, flu and RSV.
Vaxart may not actually achieve the plans, carry out the intentions
or meet the expectations or projections disclosed in our
forward-looking statements and you should not place undue reliance
on these forward-looking statements. Actual results or events could
differ materially from the plans, intentions, expectations and
projections disclosed in the forward-looking statements. Various
factors could cause actual results or events to differ materially
from these forward-looking statements, including Vaxart’s ability
to raise sufficient capital to fund the continued development of
its product candidates and complete its planned studies and trials,
that Vaxart’s product candidates may not be approved by the FDA or
non-U.S. regulatory authorities; that, even if approved by the FDA
or non-U.S. regulatory authorities, Vaxart’s product candidates may
not achieve broad market acceptance; that Vaxart may experience
manufacturing issues and delays; and other risks described in the
“Risk Factors” sections of Vaxart’s Quarterly and Annual Reports
filed with the SEC. Vaxart does not assume any obligation to update
any forward-looking statements, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190412005047/en/
Carl MauchStern Investor Relations212-362-1200vaxart@sternir.com
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Feb 2024 to Mar 2024
Vaxart (NASDAQ:VXRT)
Historical Stock Chart
From Mar 2023 to Mar 2024